Hindosh Naif, Kotala Ragarupa, Probasco Letty, Bal Swomya
Internal Medicine, St. Luke's University Health Network, Easton, USA.
Internal medicine, St Luke's University Health Network, Easton, USA.
Cureus. 2022 Apr 6;14(4):e23887. doi: 10.7759/cureus.23887. eCollection 2022 Apr.
Drug-induced lupus erythematosus (DILE) is a syndrome that manifests with symptoms similar, but with less severity, to that of systemic lupus erythematosus (SLE). Many medications are reported to be involved in DILE; however, terbinafine (Lamisil) is not a well-known causative agent of this syndrome. In this case report, we present a 22-year-old male patient with no prior medical history presented with worsening fever, rash, joint pain, and weight loss a couple of weeks after starting terbinafine. He underwent an extensive workup which revealed worsening kidney function, proteinuria, and microscopic hematuria, for which he underwent a renal biopsy which revealed class IV lupus nephritis. He was treated with prednisone taper and immunosuppressants with subsequent resolution of his symptoms. Close monitoring for the development of DILE symptoms is recommended after starting terbinafine, especially in patients with a known personal or family history of SLE.
药物性红斑狼疮（DILE）是一种综合征，其症状与系统性红斑狼疮（SLE）相似，但严重程度较轻。据报道，许多药物都与DILE有关；然而，特比萘芬（兰美抒）并不是该综合征的常见致病因素。在本病例报告中，我们介绍了一名22岁的男性患者，他既往无病史，在开始服用特比萘芬几周后出现发热、皮疹、关节疼痛和体重减轻加重。他接受了全面检查，结果显示肾功能恶化、蛋白尿和镜下血尿，为此他接受了肾活检，结果显示为IV级狼疮性肾炎。他接受了泼尼松逐渐减量治疗和免疫抑制剂治疗，随后症状得到缓解。建议在开始服用特比萘芬后密切监测DILE症状的发展，尤其是在有已知个人或家族SLE病史的患者中。
